Cargando…

Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors

PURPOSE: Omacetaxine mepesuccinate is a first-in-class cephalotaxine demonstrating clinical activity in chronic myeloid leukemia. A subcutaneous (SC) formulation demonstrated efficacy and safety in phase 1/2 trials in patients previously treated with ≥1 tyrosine kinase inhibitor. This study assessed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nemunaitis, John, Mita, Alain, Stephenson, Joe, Mita, Monica M., Sarantopoulos, John, Padmanabhan-Iyer, Swami, Nanda, Nisha, Gleich, Lyon, Benichou, Annie-Claude, Craig, Adam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3535355/ https://www.ncbi.nlm.nih.gov/pubmed/23053254 http://dx.doi.org/10.1007/s00280-012-1963-2

Ejemplares similares

Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia
por: Chen, Yaoyu, et al.
Publicado: (2014)

Omacetaxine Mepesuccinate: A New Treatment Option for Patients With Chronic Myelogenous Leukemia
por: Kurtin, Sandra E., et al.
Publicado: (2013)

Association of differential gene expression with imatinib mesylate and omacetaxine mepesuccinate toxicity in lymphoblastoid cell lines
por: Kulkarni, Hemant, et al.
Publicado: (2012)

Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate
por: Akard, Luke, et al.
Publicado: (2015)

Prediction of response and survival in patients with chronic-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate: logistic regression and landmark analyses
por: Wetzler, M, et al.
Publicado: (2015)

Homoharringtonine and omacetaxine for myeloid hematological malignancies
por: Lü, Shuqing, et al.
Publicado: (2014)

Omacetaxine mepesuccinate induces apoptosis and cell cycle arrest, promotes cell differentiation, and reduces telomerase activity in diffuse large B-cell lymphoma cells
por: ZHANG, LINA, et al.
Publicado: (2016)

Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus
por: Struemper, Herbert, et al.
Publicado: (2017)

Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinoma
por: Li, Ling, et al.
Publicado: (2021)

Pharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumors
por: Nijenhuis, Cynthia M., et al.
Publicado: (2016)

A Review of Omacetaxine: A Chronic Myeloid Leukemia Treatment Resurrected
por: Winer, Eric S., et al.
Publicado: (2018)

Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological Malignancies
por: Clements, John David, et al.
Publicado: (2019)

Bioavailability of IgG Administered by the Subcutaneous Route
por: Berger, Melvin, et al.
Publicado: (2013)

Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies
por: Mita, Monica M, et al.
Publicado: (2017)

Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer
por: Tsimberidou, Apostolia-Maria, et al.
Publicado: (2021)

Inhibitory Effects of Omacetaxine on Leukemic Stem Cells and BCR-ABL-Induced Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia in Mice
por: Chen, Yaoyu, et al.
Publicado: (2009)

Curcumin in Combination With Omacetaxine Suppress Lymphoma Cell Growth, Migration, Invasion, and Angiogenesis via Inhibition of VEGF/Akt Signaling Pathway
por: Zhang, Yu, et al.
Publicado: (2021)

A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms
por: Wolin, Edward, et al.
Publicado: (2019)

Identification of drug combinations administered by continuous subcutaneous infusion that require analysis for compatibility and stability
por: Dickman, Andrew, et al.
Publicado: (2017)

Absorption Kinetics of Subcutaneously Administered Ceftazidime in Hypoperfused Guinea Pigs
por: Ebihara, Tsuyoshi, et al.
Publicado: (2014)

Optimizing the Bioavailability of Subcutaneously Administered Biotherapeutics Through Mechanochemical Drivers
por: Collins, D. S., et al.
Publicado: (2017)

Factors Affecting the Absorption of Subcutaneously Administered Insulin: Effect on Variability
por: Gradel, A. K. J., et al.
Publicado: (2018)

Plasma pharmacokinetic profile and efficacy of meloxicam administered subcutaneously and intramuscularly to sheep
por: Woodland, Alyssa N., et al.
Publicado: (2019)

Pharmacokinetics of multivesicular liposomal encapsulated cytarabine when administered subcutaneously in dogs
por: Vazquez Fuster, Irene B., et al.
Publicado: (2020)

Once-Monthly Subcutaneously Administered Risperidone in the Treatment of Schizophrenia: Patient Considerations
por: Tchobaniouk, Lesia V, et al.
Publicado: (2019)

Diamine oxidase knockout mice are not hypersensitive to orally or subcutaneously administered histamine
por: Karer, Matthias, et al.
Publicado: (2022)

Observations on the Subcutaneous Method of Administering Medicines, from Cases Treated in Professor M'Call Anderson's Wards in the Western Infirmary of Glasgow: Subcutaneous Injection of Arsenic in Two Cases of Skin Disease
por: Moyes, John
Publicado: (1880)

Case of Snake-Bite Treated by Means of Liquor Ammoniæ, Administered Subcutaneously and Internally
por: Hogan, G.
Publicado: (1874)

Tralokinumab pharmacokinetics and tolerability when administered by different subcutaneous injection methods and rates
por: Jain, Meena, et al.
Publicado: (2017)

The Pharmacokinetics of Medetomidine Administered Subcutaneously during Isoflurane Anaesthesia in Sprague-Dawley Rats
por: Kint, Leila T., et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates Administered via Subcutaneous and Intratumoral Routes
por: Chang, Hsuan-Ping, et al.
Publicado: (2023)

Bromodomain inhibitors a decade later: a promise unfulfilled?
por: Mita, Monica M., et al.
Publicado: (2020)

Preference for Subcutaneously Administered Low-Dose Glucagon Versus Orally Administered Glucose for Treatment of Mild Hypoglycemia: A Prospective Survey Study
por: Tetzschner, Rikke, et al.
Publicado: (2019)

Sonographic features of secondary involvement of skin and subcutaneous tissues by hematologic malignancies
por: Lyu, Heng, et al.
Publicado: (2022)

Evaluation of the optimal positioning of subcutaneous butterfly when administering injectable opioids in cancer patients
por: MITREA, NICOLETA, et al.
Publicado: (2016)

Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions
por: Hövelmann, Ulrike, et al.
Publicado: (2017)

A Comparative Pharmacokinetic Analysis of Oral and Subcutaneous Meloxicam Administered to Postpartum Dairy Cows
por: Shock, Daniel, et al.
Publicado: (2019)

Economic impact of self-administered subcutaneous versus clinic-administered intravenous immunoglobulin G therapy in Alberta, Canada: a population-based cohort study
por: Ritchie, Bruce, et al.
Publicado: (2022)

Systemically Administered Reovirus-Induced Downregulation of Hypoxia Inducible Factor-1α in Subcutaneous Tumors
por: Hotani, Takuma, et al.
Publicado: (2018)

Influence of sevoflurane anesthesia with mechanical ventilation and fluid-therapy on distribution of subcutaneously administered robenacoxib in dogs
por: OYAMA, Norihiko, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3pjd7bcvj22aork3jqt0bsul1i